Scholars Central

Research articlePublished 1 Jun 2017

Clinical efficacy and safety of cardio-selective β-receptor blocker in management of AECOPD complicated with right heart failure

Authors: Wei He, Gang Xu, Cheng Zhang, Lin Xu, Ting Li, Hua Yin, Hanqiong Zhang, Huawei Li, Xiaorong Hu, Hong Zhou, Lisha Yang

Biomedical Research

Volume 28 · Issue 10 · Pages 4507–4511

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Aims: To assess the clinical efficacy and safety of administration of a low dosage of cardio-selective β- receptor blocker in treating Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD) complicated with right cardiac failure. Methods: In total, 100 AECOPD patients were randomly assigned into the experimental (n=50) and control groups (n=50). Patients in the control group received standard treatment according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD, 2013 edition). Based upon conventional therapy, those in the experimental group received oral administration of metoprolol tartrate tablets. All patients were followed up for 1 year. Results: The Forced Expiratory Volume in one second (FEV1) did not significantly differ between two groups (both P>0.05). Prior to the treatment, no statistical significance was observed in heart rate between two groups (P>0.05), whereas heart rate in the experimental group was significantly improved (P 0.05). In the experimental group, 3 patients (6.3%) suffered from adverse events, and 4 (8.4%) in the control group (P>0.05). In the experimental group, the frequency of acute exacerbation, mortality rate and NT-proBNP level were significantly lower than those in the control group (all P 0.05). Conclusion: Use of a low-dose cardio-selective β-receptor blocker can effectively alleviate AECOPD complicated with right heart failure, improve heart function and decrease the frequency of acute exacerbation. No severe adverse events are noted after administration of cardio-selective β-receptor blocker.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Biomedical Research.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalBiomedical Research
  • SubjectPathology & Lab Medicine
  • BylineArticles whose byline prints “Wei He”
  • BylineArticles whose byline prints “Gang Xu”
  • BylineArticles whose byline prints “Cheng Zhang”
  • BylineArticles whose byline prints “Lin Xu”
  • BylineArticles whose byline prints “Ting Li”
  • BylineArticles whose byline prints “Hua Yin”
  • BylineArticles whose byline prints “Hanqiong Zhang”
  • BylineArticles whose byline prints “Huawei Li”